Indivior gets FDA nod for Perseris
The Food and Drug Administration has given the OK for Indivior’s Perseris (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults.
Perseris contains risperidone, a well-established medicine for schizophrenia, and uses an extended-release delivery system to form a subcutaneous depot that provides sustained levels of risperidone over one month.
“The availability of Perseris provides physicians with a new treatment option to help address some of the challenges in treating schizophrenia,” Indivior’s CEO Shaun Thaxter said. “We understand the complex patient journey of people living with schizophrenia and recognize the important role that long-acting injectables can play. Perseris is a demonstration of our ongoing commitment to developing innovative treatments for people living with this debilitating condition.”
No comments found